Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy

BACKGROUND: The combination of docetaxel chemotherapy and androgen deprivation therapy (ADT) has become a standard treatment for patients with metastatic prostate cancer. The recently accrued Phase III CALGB 90203 trial was designed to investigate the clinical effectiveness of this treatment approac...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Beltran, Himisha, Wyatt, Alexander W, Chedgy, Edmund C, Donoghue, Adam, Annala, Matti, Warner, Evan W, Beja, Kevin, Sigouros, Michael, Mo, Fan, Fazli, Ladan, Collins, Colin C, Eastham, James, Morris, Michael, Taplin, Mary-Ellen, Sboner, Andrea, Halabi, Susan, Gleave, Martin E
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5690882/
https://ncbi.nlm.nih.gov/pubmed/28842510
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1034
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak